The Medical Advisor

HOPEWELL, NEW JERSEY—A new 42-acre campus in New Jersey gives BeiGene CEO John Oyler hope that the company can strike new partnerships in biologics. BeiGene debuted its flagship biologics manufacturing and R&D site in Hopewell, New Jersey, on Tuesday. The facility features about 400,000 square feet of commercial-stage production space, capacity for about two million vials per year and 125 employees. The campus, originally owned by Bristol Myers Squibb, has plenty of room to allow for further expansions over time. “There’s a lot of companies that do not have biologic manufacturing capabilities,” Oyler said in an interview on the sidelines of the opening ceremony. “We view ourselves as someone who, over time, became a very high-quality biologic manufacturer.” Oyler is leveraging BeiGene’s biologics experience to search for deals, like the one it  signed with  DualityBio for a preclinical antibody-drug conjugate (ADC). “I don’t think that we’re as a company saying, ‘hey, let...